Apolipoprotein B100 is a suppressor of Staphylococcus aureus-induced innate immune responses in humans and mice (Q44192854)

30 November 2017

Apolipoprotein B100 is a suppressor of Staphylococcus aureus-induced innate immune responses in humans and mice (English)

1 reference

30 November 2017

Staphylococcus aureus

1 reference

11

1 reference

30 November 2017

Stefanie Sigel

1

1 reference

30 November 2017

Sebastian Bunk

2

1 reference

30 November 2017

Thomas Meergans

3

1 reference

30 November 2017

Bianca Doninger

4

1 reference

30 November 2017

Karin Stich

5

1 reference

30 November 2017

Thomas Stulnig

6

1 reference

30 November 2017

Kurt Derfler

7

1 reference

30 November 2017

Julia Hoffmann

8

1 reference

30 November 2017

Susanne Deininger

9

1 reference

30 November 2017

Sonja von Aulock

10

1 reference

30 November 2017

language of work or name

English

0 references

publication date

28 August 2012

1 reference

European Journal of Immunology

30 November 2017

1 reference

30 November 2017

42

1 reference

30 November 2017

2983-2989

1 reference

30 November 2017

11

1 reference

Pharmacological strategies for lowering LDL cholesterol: statins and beyond

30 November 2017

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242564

Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242564

Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242564

Structure-function relationship of cytokine induction by lipoteichoic acid from Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242564

Host defenses against Staphylococcus aureus infection require recognition of bacterial lipoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242564

Recognition of lipopeptide patterns by Toll-like receptor 2-Toll-like receptor 6 heterodimer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242564

Cutting edge: TLR2-deficient and MyD88-deficient mice are highly susceptible to Staphylococcus aureus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242564

CD36 is a sensor of diacylglycerides

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242564

Lipoteichoic acid (LTA) of Streptococcus pneumoniae and Staphylococcus aureus activates immune cells via Toll-like receptor (TLR)-2, lipopolysaccharide-binding protein (LBP), and CD14, whereas TLR-4 and MD-2 are not involved

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242564

Triglyceride-rich lipoproteins as agents of innate immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242564

The role of HDL in innate immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242564

Apolipoprotein B Is an innate barrier against invasive Staphylococcus aureus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242564

Cell activation of human macrophages by lipoteichoic acid is strongly attenuated by lipopolysaccharide-binding protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242564

Lipoteichoic acid-induced lung inflammation depends on TLR2 and the concerted action of TLR4 and the platelet-activating factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242564

Evidence of immunostimulating lipoprotein existing in the natural lipoteichoic acid fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242564

Staphylococcus aureus deficient in lipidation of prelipoproteins is attenuated in growth and immune activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242564

Internalization and coreceptor expression are critical for TLR2-mediated recognition of lipoteichoic acid in human peripheral blood.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242564

Distribution and kinetics of lipoprotein-bound lipoteichoic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242564

Role of lipoteichoic acid in infection and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242564

Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242564

Low-density lipoprotein receptor-deficient mice are protected against lethal endotoxemia and severe gram-negative infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242564

Apolipoprotein A-I diminishes acute lung injury and sepsis in mice induced by lipoteichoic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242564

Structural decomposition and heterogeneity of commercial lipoteichoic Acid preparations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242564

Kupffer cell products and interleukin 1beta directly promote VLDL secretion and apoB mRNA up-regulation in rodent hepatocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242564

Upregulation of apolipoprotein B secretion, but not lipid, by tumor necrosis factor-alpha in rat hepatocyte cultures in the absence of extracellular fatty acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242564

Polypropylene glycol is a selective binding inhibitor for LTA and other structurally related TLR2 agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242564

Severe hypercholesterolaemia: therapeutic goals and eligibility criteria for LDL apheresis in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242564

21 January 2018

Identifiers

DOI

10.1002/EJI.201242564

1 reference

30 November 2017

1 reference